Characterization and interactions between piperine and ezetimibe in their Anti-hyperlipidemic efficacy using Biopharmaceutics and Pharmacokinetics

Table 5 Hepatic lipid profile effects of EZ and piperine using high fat diet method

Group	TG (µmol/L)	TC (µmol/L)	SGOT (U/mmol)	SGPT (U/mmol)	ALP (U/mmol)
I	25.63 ± 0.25	12.67 ± 0.12	26.35 ± 1.02	28.96 ± 1.02	5.23 ± 0.35
II	48.95 ± 0.36	40.29 ± 0.24	75.64 ± 1.32^a	85.43 ± 1.32^a	12.64 ± 0.64^b
III	38.76 ± 0.42	24.67 ± 0.35	35.64 ± 1.42^c	40.25 ± 1.24^a	4.52 ± 0.85^d
IV	31.24 ± 0.51	23.94 ± 0.13	30.42 ± 1.26^c	35.62 ± 1.52^c	5.24 ± 0.05
V	20.56 ± 0.36	15.86 ± 0.21	34.62 ± 1.08	32.69 ± 1.36	3.94 ± 0.04
VI	17.34 ± 0.25	12.43 ± 0.26	30.68 ± 1.27	30.64 ± 1.25	3.16 ± 0.36
VII	12.95 ± 0.22	6.26 ± 0.25	26.95 ± 1.35^c	26.49 ± 1.34^c	2.94 ± 0.57^c

Values are expressed as mean ± SEM (n = 6). ap < 0.01 and bp < 0.05 considered statistically significant as compared to normal control group; cp < 0.01 and dp < 0.05 considered statistically significant when compared to the HFD control group

ISSN: 2050-6511